The biological mechanisms underlying castration resistance of prostate cancer are not fully understood. In the present study, we examined the role of organic anion transporting polypeptides (OATPs) as importers of dehydroepiandrosterone sulfate (DHEAS) into cells to support growth under androgen-depleted conditions. Cell growth and mRNA expression of OATP genes were studied in human prostate cancer LNCaP and 22Rv1 cells under androgen-depleted conditions. The stimulatory effect of DHEAS on cell growth was investigated in LNCaP cells in which OATP1A2 had been silenced. Growth of both cell lines was stimulated by DHEAS and the effect was attenuated by STX64, an inhibitor of steroid sulfatase which can covert DHEAS to DHEA. OATP1A2 mRNA expression was increased most prominently among various genes tested in LNCaP cells grown in androgen-depleted medium. Similar results were obtained with 22Rv1 cells. Furthermore, the characteristics of 
Introduction
Gonadal androgens play a critical role in protein synthesis and cell survival in prostate tumors [1] . Therefore, androgen deprivation therapy (ADT) to remove gonadal testosterone or to antagonize androgen receptors is currently a mainstream treatment for prostate cancer. Once the disease progresses to castration-resistant prostate cancer (CRPC), it no longer responds to androgen deprivation therapy. CRPC tumor progression is considered to involve enhanced androgen receptor (AR) function, mainly due to AR gene amplification/overexpression [2] , stabilization of AR protein and increased sensitivity of AR to androgens [3] , and constitutive, ligand-independent activation [4] .
The organic anion transporter polypeptide (OATP/SLCO) family members generally mediate Na + -independent transport of amphipathic organic anion compounds, including bile salts, steroid conjugates, thyroid hormones, and oligopeptides [5, 6] . The physiological roles of these transporters are not yet fully understood, but there is compelling evidence that certain members of the OATP family promote cell proliferation and survival of human malignant tissues. We have previously shown that transport of estrone 3-sulfate via OATPs sustains the growth of hormone-dependent human breast cancer cells [7, 8] , because estrone-3-sulfate can be hydrolyzed by steroid sulfatase (STS) to estrone and eventually estradiol. We recently showed that OATP1B3 contributes to estrone 3-sulfate uptake in estrogen receptor-positive human breast cancer MCF-7 cells [9] . In addition to estrone 3-sulfate, these OATPs translocate dehydroepiandrosterone sulfate (DHEAS) [10, 11] . DHEAS is a thousand fold more abundant than testosterone in human serum [12] , and is essentially unaffected by ADT. DHEAS is hydrolyzed to DHEA by STS [13] , and DHEA can be converted to androstenedione in prostate cancer [14] , resulting in activation of AR function [15] . More recently, clinical observations have suggested that several OATPs are upregulated in castration-resistant metastatic prostate tumor tissues derived from human patients [16] ; however, it remains unclear whether OATPs play a role in prostate cancer cell survival under androgen-depleted conditions. We hypothesized that increased expression of OATPs does contribute to cell survival of androgen-dependent prostate cancer cells under androgen deprivation, by providing the cells with an increased supply of DHEAS as a precursor of active androgen.
In the present study, we investigated the expression of functional OATPs in, and the growth of, androgen-dependent prostate cancer cells. Among the OATP family members tested, OATP1A2
was found to be remarkably upregulated in AR-positive human prostate cancer cells cultured under androgen-depleted conditions. We propose that enhanced expression of OATP1A2 in these cells plays a role in progression of prostate cancer by increasing the availability of DHEAS as a precursor of active androgen, under conditions of androgen depletion. 
Materials and methods

Materials
Cell culture and growth assays
LNCaP and 22Rv1 cells were cultured in RPMI1640 (Wako Pure Chemical Industries) with penicillin (100 units/mL, Nakalai Tesque, Kyoto, Japan), streptomycin (100 μg/mL, Wako Pure
Chemical Industries) and 10% fetal bovine serum (FBS, Invitrogen). Cells were cultured in a humidified atmosphere containing 5% CO 2 at 37 o C. For the cell growth assay, cells were cultured in RPMI1640 with penicillin (100 units/mL), streptomycin (100 μg/mL) supplemented with FBS or charcoal-stripped FBS (CSS, Invitrogen) in the presence or absence of androgen and/or STX64 (also known as 667 coumate or 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta-
[c]chromen-3-yl sulfamate, Sigma Aldrich, St. Louis, MO), which is a tricylic coumarin-based sulfamate that inhibits steroid sulfatase. The growth-stimulatory effect of androgens, including DHEAS, was evaluated by measuring cell growth after cells were plated at a density of 1.5 to 2.4 × 10 4 cells/cm 2 on a 96-well tissue culture plate. In general, once cells became attached to the plate, a test androgen or DMSO (at 0.1% of the final concentration) was added to the well, and cell growth was monitored for up to 9 days by means of sulforhodamine B (SRB, Sigma Aldrich) assay as previously described [17] .
Gene expression profiling assay
LNCaP cells were cultured in RPMI1640 with penicillin (100 units/mL), streptomycin (100 Gene, Tokyo, Japan). Microarray experiments were performed and data were analyzed according to the manufacturer's instructions (Agilent Technologies, Santa Clara, CA). In brief, 300 ng of total RNA was subjected to linear amplification and Cy3 labeling using the Low RNA Input
Linear Amplification Kit (Agilent Technologies), and then hybridized to a 44-K Whole Human
Genome Microarray (Agilent Technologies). Data were extracted using Feature Extraction software (version 9.5.3) and analyzed using GeneSpring GX software (version 11.0).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was prepared from cells using Isogen reagent (Nippon Gene). mRNA expression of OATP1A2, OATP1B1, OATP1B3, OATP2B1, OAT2, OAT3, and OAT4 was measured by quantitative RT-PCR (qRT-PCR), using Brilliant SYBR Green QPCR Master Mix (Agilent Technologies). The fold change in mRNA expression of transporter genes was normalized to hypoxanthine guaninephosphoribosyl-transferase 1 (HPRT1) using the 2-ΔΔ threshold cycles (Ct) method [18] . Primer sequences specific to transporter genes tested are listed in Table 1 .
[ 3 H]DHEAS cellular uptake assay
Intracellular accumulation of DHEAS was evaluated by means of uptake assays as described previously [17] . Briefly, cells were plated at a density of 1. 
Western blot
To determine protein expression of OATP1A2, cells were collected and lysed in RIPA buffer 
Construction of OATP1A2-Transfected LNCaP Cells
LNCaP cells were transfected with pcDNA3.1/OATP1A2 or pcDNA3.1 alone (Invitrogen), and then selected with 800 μg/mL of G418 (Wako Pure Chemicals). Enhanced OATP1A2 expression was verified by uptake study of [ 3 H]DHEAS (0.5 μCi/mL) for up to 5 min and
Western blotting using anti-human OATP1A2 rabbit IgG.
OATP1A2 knockdown in LNCaP cells
To develop prostate cancer cell lines with knockdown of OATP1A2, double-stranded DNA containing a hairpin sequence for the targeted site (5'-tattctttggctgccatacct-3') and Two days later, selection of transfected cells was started with blasticidin (2 μg/mL, Invitrogen).
After about 3 weeks, blasticidin-resistant and EmGFP-positive cells were used for the proliferation studies and subjected to RT-PCR analysis.
Results
DHEAS-induced cell growth and PSA expression in androgen receptor-positive prostate cancer cells
In order to determine whether DHEAS can stimulate cell growth of androgen receptor-positive human prostate cancer LNCaP cells, cell growth was measured in androgen-depleted medium.
The cell growth was stimulated by DHEAS in a concentration-dependent manner. At a physiologically relevant serum concentration of DHEAS (5 μM Figure 1D ).
Alteration in organic anion transporter levels in androgen receptor-positive prostate cancer cells
DHEAS is an organic anion at physiological pH, and its uptake requires carrier-mediated transport across plasma membranes. We therefore performed a microarray analysis to compare the gene expression profiles of transporters that might be involved in DHEAS uptake between LNCaP cells grown in normal and androgen-depleted culture medium. Table 2 summarizes the genes whose expression altered by more than 1.5 times under the androgen-depleted condition;
there were significant increases in several OATP genes, including OATP5A1, 1A2, and 1B1.
This was confirmed by qRT-PCR (Figure 2A ). OATP1A2 mRNA expression was increased most markedly among the genes tested, and was 3.6-and 6.4-fold greater in LNCaP cells cultured in CSS-containing medium on Days 3 and 7, respectively, than on Day 1; however, no such increase was observed in LNCaP cells cultured for 7 days in normal medium (data not shown). Similarly, mRNA expression levels of OATP2A1 and 1B1 on Day 7 were increased 3.4-and 7.4-fold, respectively ( Figure 2A ). Table 3 and SLC10A4 appeared to be upregulated when the medium was deprived of androgen. Further qRT-PCR analysis showed that OATP1A2 mRNA expression was increased 3.7-fold in 22Rv1 cells, confirming DHT-mediated negative regulation of the transcription ( Figure 2E ).
Enhanced cellular uptake of DHEAS under androgen deprivation
To study the contribution of OATPs to cellular uptake of DHEAS in LNCaP cells, intimal (tetra-ethylammonium and 1-methyl-4-phenylpyridinium) had no effect ( Figure 3A) . The uptake was tolerant of Na + replacement with Li + , K + and NMG + ( Figure 3B ). Accordingly, decreased the uptake, implying that cellular uptake of DHEAS is regulated by OATPs whose expression is negatively regulated by androgen, such as OATP1A2 ( Figure 3C ).
Contribution of OATP1A2 to DHEAS-induced cell growth in LNCaP cells
To To date, little is known about the role of OATPs in prostate cancer cells, although enhanced expression of OATPs in prostate tumors has been reported [16, 19] . Among them, OATP1B3 may be an important player for driving cell proliferation of prostate cancer cells, because it facilitates testosterone uptake into cells [19] . A more recent study with patient-derived prostate tumor specimens indicated that mRNA expression of six SLCO genes, including SLCO1B3 and 2B1, was enhanced several-fold in CRPC metastases, compared to untreated prostate cancer, implying their association with prostate cancer-specific motility [16] . In the present study, we observed remarkable upregulation of OATP1A2 mRNA expression, as well as significant increases of OATP2A1 and 1B1 on Day 7 in CSS-containing culture medium, whereas expression of OATP2B1 and OATP1B3 was increased only moderately and slightly, respectively ( Figure 2) . We also found a stimulatory effect of DHEAS on growth of LNCaP and 22Rv1 cells ( Figure 1) ; therefore, we focused here on DHEAS transport by OATPs, even though several other substrates are also commonly transported by the OATPs whose expression is enhanced.
Several classes of SLC transporters have been shown to mediate DHEAS uptake, including OATP1A2, 1B1, 1B3, and 2B1 [10, 11] , OAT2, 3, and 4 [20] [21] [22] , and Na + -dependent taurocholate cotransporting polypeptide (NTCP) [23] . Hence, we conducted gene expression profiling of human prostate cancer LNCaP cells cultured under androgen-depleted conditions (Table 2A and Table 3 ). Microarray analysis suggests that OATP molecules are preferentially upregulated in LNCaP cells cultured in the absence of androgens, and this idea was supported by evidence that the functional characteristics of DHEAS transport in LNCaP cells resemble those of OATP-mediated transport ( Figure 3A and 3B). Among several OATPs whose expression is enhanced by androgen deprivation, OATP1A2 showed the greatest increase in expression, and interestingly, its expression is negatively regulated by androgen signaling ( Figure 2C ). The increase of OATP1A2 mRNA was confirmed by Western blotting, showing two distinct bands around 75 and 100 kDa. This result agrees with two bands previously shown for OATP1A2 expressed in breast cancer cells in Western blotting, suggesting that OATP1A2 is glycosylated [24] . We found that expression of OATP1A2 was increased in LNCaP and 22Rv1 cells cultured under conditions of hormone deprivation, and the increase was consistent with the increase of initial uptake of DHEAS in LNCaP cells ( Figure 3C ). Ligand-bound nuclear hormone receptors activate transcription in the classical mode of receptor action, by binding to the regulatory sequence of the target gene promoter in dimer form. However, they also silence gene expression in various ways, such as through recruiting co-repressor, changing chromatin structure and accessibility, or inhibiting signaling pathways via cross-talk. For instance, androgen receptor has been shown to act as a ligand-dependent trans-repressor of activator protein-1 (AP-1) activity, resulting in attenuation of AP-1-activated gene expression [25] . The proximal promoter region of OATP1A2 has been characterized, and contains active cis-elements for several hepatocyte nuclear factors, a TAATAT box, and a putative AP-1 binding site [26] ; it was therefore speculated that androgen-dependent negative regulation may be due to inhibition of AP1 by ligand-bound androgen receptor in LNCaP cells. Further study is needed to clarify the precise mechanism of repression of OATP1A2 expression by active androgens.
Because DHEAS is an inactive precursor of DHEA, it has to be activated by desulphation. It was reported that DHEAS is hydrolyzed by STS in LNCaP cells [27] and the expression of STS is increased in prostate cancer cells, compared to non-malignant prostate tissues, as determined by immunohistochemical staining [28] . In the present study, expression of STS mRNA was detected in LNCaP cells, and this expression was not affected under androgen-depleted conditions ( Figure 1C ). Furthermore, cell growth of LNCaP cells was significantly reduced in the presence of STX64 ( Figure 1B) , while PSA mRNA expression in LNCaP cells was increased in the presence of DHEAS ( Figure 1D ). These results suggest that DHEAS undergoes metabolism at least to DHEA, mediated by STS. DHEA thus generated may have a weak androgenic potential to activate AR directly, but is more likely converted to T or DHT via 3b-hydroxysteroid dehydrogenase (3bHSD), since cell proliferation of LNCaP cells in the presence of DHEA was reported to be suppressed by inhibition of 3bHSD [15] . Although DHEA is present in human serum (~ 5 nM), the DHEAS concentration in serum (3 ~ 5 μM) is almost a thousand fold greater [12] ; therefore, DHEAS may be taken up by prostate cancer cells via OATPs as a source of DHEA to compensate for the shortage of androgen in serum. This notion is supported by the experimental finding that knockdown of OATP1A2 in LNCaP cells resulted in loss of the cell growth response to DHEAS (Figure 4) . Thus, concomitant use of a blocker of OATP1A2 may be pharmacologically important to more efficiently eradicate prostate cancer cells during the course of ADT. It is also noteworthy that, among non-synonymous polymorphisms which have been reported in SLCO1A2 gene, decreased transport of estrone sulfate was reported in c.767A>C (rs11568563, E172D) and c.655A>T (rs45502302, N135I) [29, 30] . Therefore, the efficacy of ADT might be affected in prostate cancer patients with these genotypes, of which c.767A>C is relatively frequent in Europeans and Americans (5.3%).
Conclusion
In conclusion, our results indicate that OATP1A2 plays a role in the growth of prostate cancer cells under androgen-depleted conditions by supplying DHEAS as an alternative source of androgen, so that the cells can survive to acquire castration resistance. This is a novel mechanism underpinning the progression of advanced prostate cancer to the castration-resistant state. Hence, OATPs (especially OATP1A2) may be a pharmacological target for more effective treatment of prostate cancer. In other words, pharmacological inhibition of OATP1A2-mediated influx transport of DHEAS in conjunction with ADT might be effective to improve the prognosis of prostate cancer patients. Table 3 Quantitative 
